稳定性缺血性心脏病合并心衰或左室功能不全患者的初始侵入性与保守治疗:ISCHEMIA试验分析
ISCHEMIA试验纳入5179例稳定性缺血性心脏病且至少中度缺血患者,左室射血分数≥35%。基线有HF/LVD者398例(7.7%),中位随访3.2年。有HF/LVD者主要终点事件率更高;在该亚组中初始侵入性策略较保守策略降低主要终点事件率(17.2% vs 29.3%,4年事件率差-12.1%),交互作用P=0.055。
要点
- 合并HF/LVD的稳定性缺血性心脏病患者心血管事件风险显著更高。
- HF/LVD亚组中初始侵入性策略可能改善无事件生存,但为假设生成性。
- 该结果不应推广至所有稳定性缺血性心脏病患者。
核心结论
- 合并HF或LVD的稳定性缺血性心脏病患者主要终点事件风险增加。
- 在高危亚组(HF且LVEF 35%-45%)中,初始侵入性策略与更好的无事件生存相关,但结果仅为假设生成性。
研究设计与样本
- ISCHEMIA随机对照试验的事后亚组分析,共5179例LVEF≥35%的稳定性缺血性心脏病伴至少中度缺血患者。
- 比较基线有HF/LVD(n=398,7.7%)与无HF/LVD者的心血管结局,中位随访3.2年。
主要发现
- 有HF/LVD者4年主要终点累积发生率22.7% vs 无HF/LVD者13.8%。
- 有HF/LVD者心血管死亡或心肌梗死4年发生率19.7% vs 12.3%。
- 有HF/LVD者全因死亡或心衰4年发生率15.0% vs 6.9%。
- HF/LVD亚组侵入性 vs 保守策略主要终点4年事件率17.2% vs 29.3%,差值-12.1%(95%CI -22.6至-1.6%)。
- 无HF/LVD亚组侵入性 vs 保守策略主要终点4年事件率13.0% vs 14.6%,差值-1.6%(95%CI -3.8%至0.7%),交互作用P=0.055。
关键数值与推荐
- HF/LVD定义为基线有HF病史或LVEF 35%-45%;亚组中177例HF且LVEF>45%,28例HF且LVEF 35%-45%,193例LVEF 35%-45%但无HF病史。
临床怎么用
- 对稳定性缺血性心脏病合并HF或LVD且LVEF≥35%的患者,可考虑初始侵入性策略以降低心血管事件风险。
- 决策时应个体化评估,尤其参考LVEF和HF病史,并认识到证据的假设生成性质。
局限性
- HF/LVD亚组样本量小(n=398),事件数有限。
- 结果为事后亚组分析,交互作用P=0.055未达传统显著性。
- 作者明确指出结果仅为假设生成性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Whether an initial invasive strategy in patients with stable ischemic heart disease and at least moderate ischemia improves outcomes in the setting of a history of heart failure (HF) or left ventricular dysfunction (LVD) when ejection fraction is ≥35% but <45% is unknown. METHODS: Among 5179 participants randomized into ISCHEMIA (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches), all of whom had left ventricular ejection fraction (LVEF) ≥35%, we compared cardiovascular outcomes by treatment strategy in participants with a history of HF/LVD at baseline versus those without HF/LVD. Median follow-up was 3.2 years. RESULTS: There were 398 (7.7%) participants with HF/LVD at baseline, of whom 177 had HF/LVEF >45%, 28 HF/LVEF 35% to 45%, and 193 LVEF 35% to 45% but no history of HF. HF/LVD was associated with more comorbidities at baseline, particularly previous myocardial infarction, stroke, and hypertension. Compared with patients without HF/LVD, participants with HF/LVD were more likely to experience a primary outcome composite of cardiovascular death, nonfatal myocardial infarction, or hospitalization for unstable angina, HF, or resuscitated cardiac arrest (4-year cumulative incidence rate, 22.7% versus 13.8%; cardiovascular death or myocardial infarction, 19.7% versus 12.3%; and all-cause death or HF, 15.0% versus 6.9%). Participants with HF/LVD randomized to the invasive versus conservative strategy had a lower rate of the primary outcome (17.2% versus 29.3%; difference in 4-year event rate, -12.1% [95% CI, -22.6 to -1.6%]), whereas those without HF/LVD did not (13.0% versus 14.6%; difference in 4-year event rate, -1.6% [95% CI, -3.8% to 0.7%]; P interaction = 0.055). A similar differential effect was seen for the primary outcome, all-cause mortality, and cardiovascular mortality when invasive versus conservative strategy-associated outcomes were analyzed with LVEF as a continuous variable for patients with and without previous HF. CONCLUSIONS: ISCHEMIA participants with stable ischemic heart disease and at least moderate ischemia with a history of HF or LVD were at increased risk for the primary outcome. In the small, high-risk subgroup with HF and LVEF 35% to 45%, an initial invasive approach was associated with better event-free survival. This result should be considered hypothesis-generating. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01471522.
引用
- Lopes RD, Alexander KP, Stevens SR, et al. Initial Invasive Versus Conservative Management of Stable Ischemic Heart Disease in Patients With a History of Heart Failure or Left Ventricular Dysfunction: Insights From the ISCHEMIA Trial. Circulation. 2020. PMID: 32862662. doi:10.1161/CIRCULATIONAHA.120.050304
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。